Table 3.
Table showing studies of Navitoclax in a range of cancer models and trials.
| Reference | Model | Drug | Cancer Type | Effect |
|---|---|---|---|---|
| Tan et al. 2011 [94] | In vitro | Naviticlax+Paclitaxel | Non-small cell lung cancer | More than additive cell killing with combination |
| Stamelos et al. 2013 [95] | In vitro | Naviticlax+Paclitaxel or Carboplatin | Ovarian cancer | More than additive cell killing with combination |
| Jeong et al. 2019 [96] | In vitro | Vemurafenib+Navitoclax | Papillary thyroid cancer | Enhanced growth arrest and increase apoptosis with combination |
| Nakajima et al. 2016 [97] | In vitro | Vorinostat+Navitoclax | Small cell lung cancer | Increased induction of apoptosis with combination |
| Gonzalez-Gualda et al. 2020 [93] | In vitro and ex vitro | Galactose conjugated Navitoclax+Cisplatin | Lung cancer | Increased cell killing with combination. Reduced platelet toxicity in ex vivo blood |
| Ackler et al. 2012 [98] | In vivo mouse model | Bendamustine+Navitoclax±Rituximab | Non-Hodgkins lymphoma | Enhanced efficacy in combination |
| Tolcher et al. 2015 [99] | Phase 1 clinical trial | Irinotecan+Navitoclax | Advanced solid tumours, n = 31 | 6% rate of partial response |
| Kipps et al. 2015 [100] | Phase 2 clinical trial | Rituximab+Navitoclax | Chronic lymphocytic lymphoma | Combination increase progression free survival and response rates |
| Rudin et al. 2012 [101] | Phase 2 clinical trial | Single agent navitoclax | Relapsed small cell lung cancer, n = 39 | 23% static disease, 2.6% partial response |